4 assets in Melanoma, Cutaneous Malignant, Susceptibility To, 3

Therapeutic assets addressing Melanoma, Cutaneous Malignant, Susceptibility To, 3, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Abemaciclib Melanoma, Cutaneous Malignant, Susceptibility To, 3	Eli Lilly and Company	P3	B (60)
Abiraterone Melanoma, Cutaneous Malignant, Susceptibility To, 3	Eli Lilly and Company	P3	B (60)
Prednisolone Melanoma, Cutaneous Malignant, Susceptibility To, 3	Eli Lilly and Company	P3	B (60)
Prednisone Melanoma, Cutaneous Malignant, Susceptibility To, 3	Eli Lilly and Company	P3	B (60)